Press Release

Megaphone image

ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP® in Immune Cell Cryopreservation Testing

St. Marys, West Virginia

ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) ( and Proactive Immune Sciences ( today announce that they have entered into a joint research collaboration. The goal of the research will be to test the effect of the patented anti-aging glycopeptide AAGP® on the immune cell cryopreservation protocols used by Proactive Immune Sciences.

“We are excited about this new joint research collaboration and hope AAGP® has some of the same positive effects, with respect to cryopreserving immune cells, that it is having on other cell lines,” says Jeff Schulz, CEO, Proactive Immune Sciences. “We are hoping to prove through our research that AAGP® will have a positive affect on helping immune cells recover from the cryopreservation process. Any improvement in cell survival rate, or cell function could have significant, positive benefits for future treatments using cryopreserved immune cells.

Pending a successful outcome of our research, the intent is for Proactive to enter into a licensing agreement with ProtoKinetix for the cryopreservation of immune cells. This will give Proactive customers the benefit of knowing their stored immune cells will perform at the highest levels possible should they require them for any immune cell based cancer or immune system reconstitution later in their life.”

About Immune Cell Banking

The initial phase of the research is expected to conclude later in 2017. Partial funding for the project has been provided by The National Research Council’s Industrial Research Assistance Program.

About the National Research Council’s Industrial Research Assistance Program

Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. These cells can be used later on for any form of immunotherapy the client might require.

“We welcome the opportunity to show the effectiveness of our AAGP® molecule in another rapidly expanding, high-demand, commercial arenafurther demonstrating the versatility of this molecule’s ability to protect cells in different clinical situations,” said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, a Phase 1 human clinical trial has begun at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.

About Proactive Immune Sciences Corporation

Proactive is a life sciences company that is establishing a new service whereby customers can safely store a sample of their healthy immune cells today, while they are younger and healthier. Using the latest technology and approved regulatory protocols, Proactive will cryogenically freeze and store their immune cells. These individuals will have access to their own stored cells as a resource for future immune intervention or regenerative therapy or immune system reconstitution.

To subscribe to e-mail updates please follow the following link:

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on February 21, 2017. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here

For further information, please contact:

Clarence E. Smith
President and Chief Executive Officer

Telephone: 304-299-5070
Email: [email protected]
Twitter: @ProtoKinetix

Explore Protokinetix

Create a secure online account

Research pipeline

We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.